NASDAQ trade advice (B): US health care stock | 6-7% gain | USA stock trading signal on 11 Sep 2024

Stock Market
NASDAQ, United States of America

Target hit. Trade closed.

NASDAQ: EXEL

11 Sep 2024
17 Sep 2024
17 Sep 2024
4 days
Loss per
100,000 USD
Stop-loss
25
Buy Advice
11 Sep 2024
25.75 - 26.25
Target 1
17 Sep 2024
27.75
Target 2
17 Sep 2024
28
Profit per
100,000 USD
4 days
6,107
25
25.75 - 26.25
27.75
28
6,107
  • Buy
  • Buy
    Range
  • Target
  • Stoploss
  • Upside
    Potential
  • Trade
    Duration
  • Exelixis
  • 25.75 – 26.25
  • 27.75 – 28
  • Below 25
  • 6% – 7%
  • 12 - 14 Days
  • Buy Exelixis
  • Buy
    Range
    25.75 – 26.25
  • Target 27.75 – 28
  • Stoploss Below 25
  • Upside
    Potential
    6% – 7%
  • Trade
    Duration
    12 - 14 Days
  • * Once the first target hit, reset the StopLoss at your buying price.
    * Trade durations are approximate; actual holding period may vary.

    Exelixis (NASDAQ: EXEL) - Stock Overview

  • NASDAQ code
  • Stock Name
  • Sector
  • 52 Weeks High
  • 52 Weeks Low
  • EXEL
  • Exelixis
  • Health Care
  • 27.53
  • 18.64
  • NASDAQ code EXEL
  • Stock Name Exelixis
  • Sector Health Care
  • 52 Weeks High 27.53
  • 52 Weeks Low 18.64
  • Company profile

    Exelixis, Inc. is an oncology company focused on finding and marketing new treatments for difficult cancers in the U.S. It offers CABOMETYX tablets for advanced renal cell carcinoma patients who have had prior anti-angiogenic therapy, and COMETRIQ capsules for progressive metastatic medullary thyroid cancer. Both drugs are based on cabozantinib, which blocks various tyrosine kinases like MET, AXL, RET, and VEGF receptors. The company also provides COTELLIC, a MEK inhibitor for some advanced melanoma cases, and MINNEBRO, an oral hypertension blocker in Japan. Exelixis is working on zanzalintinib, a next-gen oral tyrosine kinase inhibitor targeting VEGF and MET, as well as XB002, an ADC targeting tissue factor. It has partnerships with several pharmaceutical firms and a clinical agreement with Sairopa B.V. for ADU-1805. Founded in 1994 and originally named Exelixis Pharmaceuticals, Inc., it rebranded to Exelixis, Inc. in February 2000 and is based in Alameda, California.

  • Exelixis (NASDAQ: EXEL) vs NASDAQ - Relative Strength Comparison

    The image highlights Exelixis's performance over the last year versus NASDAQ.
    Relative Performance - Last 1 Year
    EXEL —   NASDAQ —

  • Exelixis (NASDAQ: EXEL) - Technical Analysis (Daily)

    Exelixis - Technical Analysis chart on Daily Price and Volume
    Exelixis - Technical Analysis chart on Daily Price and Volume

    • Following the breakdown of the Rising Wedge pattern, the price entered an extended consolidation phase.
    • During this time, a Rounding Bottom pattern emerged on the chart.
    • Once the price broke above the neckline of the Rounding Bottom, it experienced a upward movement but faced resistance near the 27.5 level.
    • After a short pullback, the stock price is currently on an upward trend, with expectations that it may exceed the immediate resistance and sustain its position above that level.
  • Exelixis (NASDAQ: EXEL) - RSI Indicator

    Exelixis stock analysis based on RSI indicator
    Exelixis - RSI indicator

    • Current RSI of this stock is 61.60, which indicates the strength of buyers.

  • Exelixis (NASDAQ: EXEL) - ADX & DI Indicator

    Exelixis stock analysis based on ADX & DI indicator
    Exelixis - ADX & DI indicator

    • Increasing ADX value above 20, indicated the strength of the trend, thereby uptrending ADX confirms the bullish or bearish supportive decisions. Along with the rising ADX, and the +DI is above (or crossing) -DI, indicates the long trades should be favoured.

  • Exelixis (NASDAQ: EXEL) - EMA Crossover

    Exelixis stock analysis based on EMA Crossover
    Exelixis - EMA Crossover

    • The short length exponential moving average (10 EMA) has crossed the long length exponential moving average (20 EMA) from the below, generates bullish signal. Last day’s candle has closed above all these moving averages. This suggests buyers are taking interest in this stock.

  • Conclusion - Exelixis (NASDAQ: EXEL) Stock Price Forcast

    Based on our positional trading in USA stocks, Exelixis stock price target will be USD 27.75 - USD 28 in the next 12-14 trading sessions.

  • Share with
    0 0 votes
    Article Rating
    Subscribe
    Notify of
    guest
    0 Comments
    Inline Feedbacks
    View all comments

    Join Our Telegram Channel for US Stock Market Update

    USA Stock Analysis

    The stock trading advice is prepared by the Naranj Capital team under the guidance of Arijit Banerjee, CMT, CFTe.
    Maximize your return with our precise trading advice on the USA stock exchange! We recommend an technology stock poised for
    Get expert short-term trading advice for the USA stock exchange. This energy stock is projected to deliver 5%-6% returns in
    Short Term Trading Alert: This Consumer Discretionary stock has the upside potential of 5-6% in 14-15 trading days. Swing Trading
    Short Term Trading Advice: Qualcomm Inc (NASDAQ - QCOM) has the upside potential of 5-6% in 14-15 trading days

    Join Our Telegram Channel for Saudi Stock Market Update

    Saudi Stock Analysis

    Maximize your return with our precise trading advice on Saudi stock exchange Tadawul! We recommend buying Arabian Pipes (Tadawul 2200)
    Short Term Trading Alert: This Saudi health care equipment stock has the upside potential of 8-10% in 12-14 trading days.
    Get expert short-term trading advice for the Saudi stock exchange Tadawul. Buy Etihad Atheeb Telecom (Tadawul 7040) for 13%-16% returns
    Short term trading advice for Shariah compliant Tadawul stocks. Buy Riyadh Cables Group (Tadawul 4142) with potential for 15-17% returns
    Maximize your trading returns in Saudi stock exchange Tadawul! Discover a shariah halal materials sector stock having 7-9% gains in
    Details of Arijit Banerjee

    Arijit Banerjee CMT CFTe is a seasoned expert in the financial industry, boasting decades of experience in trading, investment, and wealth management. As the founder and chief strategist of Naranj Capital, he’s built a reputation for providing insightful research analysis to guide investment decisions.

    Arijit’s credentials are impressive, holding both the Chartered Market Technician (CMT) and Certified Financial Technician (CFTe) designations. These certifications demonstrate his expertise in technical analysis and financial markets.

    Through Naranj Capital, Arijit shares his market insights and research analysis, offering actionable advice for investors. His work is featured on platforms like TradingView, where he publishes detailed analysis and recommendations.

    If you’re interested in learning more about Arijit’s work or Naranj Capital’s services, you can reach out to them directly through their website